Continuous furosemide does not prevent cardiopulmonary bypass-related acute kidney injury in minimally invasive cardiac surgery: the randomized furosemide trial
The Journal of ExtraCorporeal Technology · 2025
DOI: 10.1051/ject/2025042 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift The Journal of ExtraCorporeal Technology, 2025. Verfasst von Tomohisa Takeichi und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Engineering, Kitaharima Medical Center, 926-250, Ichiba-cho, Ono-shi, Hyogo, 675-1392, Japan. Hauptthemen laut MEDLINE: Acute Kidney Injury, Cardiac Surgical Procedures, Cardiopulmonary Bypass, Furosemide. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objectives
This study aimed to assess whether continuous furosemide administration during cardiopulmonary bypass (CPB) in minimally invasive cardiac surgery (MICS) reduces the incidence of cardiac surgery-associated acute kidney injury (AKI).
Methods
A total of 100 patients undergoing MICS with CPB were randomly assigned to receive either continuous furosemide infusion or no continuous furosemide during CPB. The primary endpoint was the incidence of AKI. Secondary endpoints included the cardiac surgery-associated neutrophil gelatinase-associated lipocalin (CSA-NGAL) score, urine output within 12 h postoperatively, postoperative furosemide dose requirements, red blood cell transfusion volume, PaO 2 /FiO 2 ratio, duration of mechanical ventilation, length of stay in the intensive care unit (ICU) and hospital, and in-hospital mortality.
Results
AKI occurred in 8 patients (16%) in the continuous furosemide group and in 6 patients (12%) in the non-continuous group (relative risk, 0.72; 95% CI, 0.23–2.23). Among the secondary endpoints, urine output within the first 3 h postoperatively and the PaO 2 /FiO 2 ratio were significantly higher in the continuous furosemide group. However, subgroup analyses revealed no significant differences between the two groups.
Conclusions
Continuous furosemide administration during CPB did not effectively reduce the incidence of AKI. However, it was associated with a significant increase in postoperative urine output and an improvement in the PaO 2 /FiO 2 ratio.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Engineering, Kitaharima Medical Center, 926-250, Ichiba-cho, Ono-shi, Hyogo, 675-1392, Japan.
- Cardiovascular Surgery, Kitaharima Medical Center, 926-250, Ichiba-cho, Ono-shi, Hyogo, 675-1392, Japan.
ORCID-Profile: Tomohisa Takeichi
Zitieren
APA
Takeichi, T., Morimoto, Y., Yamada, A., Tanaka, T., Fujiwara, K., Sato, M., Toma, R., Mitsui, K., Sugita, T., Yamada, H., & Gan, K. (2025). Continuous furosemide does not prevent cardiopulmonary bypass-related acute kidney injury in minimally invasive cardiac surgery: the randomized furosemide trial. The Journal of ExtraCorporeal Technology. https://doi.org/10.1051/ject/2025042
Vancouver
Takeichi T, Morimoto Y, Yamada A, Tanaka T, Fujiwara K, Sato M, et al. Continuous furosemide does not prevent cardiopulmonary bypass-related acute kidney injury in minimally invasive cardiac surgery: the randomized furosemide trial. The Journal of ExtraCorporeal Technology. 2025. doi:10.1051/ject/2025042
BibTeX
@article{Takeichi2025,
author = {Takeichi, Tomohisa and Morimoto, Yoshihisa and Yamada, Akitoshi and Tanaka, Takanori and Fujiwara, Kunihiro and Sato, Masanobu and Toma, Ryo and Mitsui, Kiyoto and Sugita, Takumi and Yamada, Hiroki and Gan, Kunio},
title = {Continuous furosemide does not prevent cardiopulmonary bypass-related acute kidney injury in minimally invasive cardiac surgery: the randomized furosemide trial},
journal = {The Journal of ExtraCorporeal Technology},
year = {2025},
doi = {10.1051/ject/2025042}
}
EUVIMED